HMTXF (Hemostemix) Total Receivables: $0.04 Mil (As of Mar. 2026)


What is Hemostemix Total Receivables?

Hemostemix HMTXF Total Receivables is $0.04 Mil as of Mar. 2026.

Hemostemix's Total Receivables for the quarter that ended in Mar. 2026 was $0.04 Mil.

Hemostemix Total Receivables Historical Data

* Premium members only.

The historical data trend for Hemostemix's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemostemix Total Receivables Chart

Hemostemix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.10 0.02 0.16 0.05

Hemostemix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.03 0.02 0.05 0.04

Hemostemix Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.04 Mil mean?
Hemostemix (HMTXF) has a Total Receivables of $0.04 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Hemostemix and its competitors.
Is Hemostemix's Total Receivables too high?
Hemostemix's current Total Receivables is $0.04 Mil.
How does Hemostemix's Total Receivables compare to VRTX and REGN?
Hemostemix's Total Receivables of $0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Hemostemix and its competitors. Hemostemix's current Total Receivables is $0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemostemix stock overvalued right now?
Hemostemix (HMTXF) has a current Total Receivables of $0.04 Mil. The current Total Receivables is $0.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Hemostemix (HMTXF), the current Total Receivables is $0.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemostemix Business Description

Other Exchanges 2VF0:GermanyHEM:Canada
Address 707 - 7th Avenue SouthWest, Suite 1150, Calgary, AB, CAN, T2P 3H6
Hemostemix Inc is a clinical-stage biotechnology company whose principal business is to develop, manufacture, and commercialize blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments. Its product ACP-01 is derived from a patient's own blood and evaluated in clinical research for ischemic conditions, including Cardiovascular Ischemia, Peripheral Arterial Disease (PAD), Chronic Limb Threatening Ischemia (CLTI), and Vascular Dementia.